402 related articles for article (PubMed ID: 29525346)
1. NKG2D and its ligands in cancer.
Dhar P; Wu JD
Curr Opin Immunol; 2018 Apr; 51():55-61. PubMed ID: 29525346
[TBL] [Abstract][Full Text] [Related]
2. NKG2D Receptor and Its Ligands in Host Defense.
Lanier LL
Cancer Immunol Res; 2015 Jun; 3(6):575-82. PubMed ID: 26041808
[TBL] [Abstract][Full Text] [Related]
3. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
[TBL] [Abstract][Full Text] [Related]
4. NKG2D signaling in cancer immunosurveillance.
López-Soto A; Huergo-Zapico L; Acebes-Huerta A; Villa-Alvarez M; Gonzalez S
Int J Cancer; 2015 Apr; 136(8):1741-50. PubMed ID: 24615398
[TBL] [Abstract][Full Text] [Related]
5. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
6. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
[TBL] [Abstract][Full Text] [Related]
7. NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment.
Frazao A; Rethacker L; Messaoudene M; Avril MF; Toubert A; Dulphy N; Caignard A
Front Immunol; 2019; 10():661. PubMed ID: 30984204
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy using NKG2D and DNAM-1 systems.
Morisaki T; Onishi H; Katano M
Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658
[TBL] [Abstract][Full Text] [Related]
9. NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8(+) T cells.
Whitman E; Barber A
Mol Immunol; 2015 Feb; 63(2):268-78. PubMed ID: 25089028
[TBL] [Abstract][Full Text] [Related]
10. NKG2D Defines a Subset of Skin Effector Memory CD8 T Cells with Proinflammatory Functions in Vitiligo.
Jacquemin C; Martins C; Lucchese F; Thiolat D; Taieb A; Seneschal J; Boniface K
J Invest Dermatol; 2020 Jun; 140(6):1143-1153.e5. PubMed ID: 31877315
[TBL] [Abstract][Full Text] [Related]
11. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
12. NKG2D CARs as cell therapy for cancer.
Sentman CL; Meehan KR
Cancer J; 2014; 20(2):156-9. PubMed ID: 24667963
[TBL] [Abstract][Full Text] [Related]
13. NKG2D Ligand Shedding in Response to Stress: Role of ADAM10.
Zingoni A; Vulpis E; Loconte L; Santoni A
Front Immunol; 2020; 11():447. PubMed ID: 32269567
[TBL] [Abstract][Full Text] [Related]
14. The role of the NKG2D receptor for tumor immunity.
Coudert JD; Held W
Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326
[TBL] [Abstract][Full Text] [Related]
15. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.
Mincheva-Nilsson L; Baranov V
Semin Cancer Biol; 2014 Oct; 28():24-30. PubMed ID: 24602822
[TBL] [Abstract][Full Text] [Related]
16. Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity.
Alves E; McLeish E; Blancafort P; Coudert JD; Gaudieri S
Front Immunol; 2021; 12():712722. PubMed ID: 34456921
[TBL] [Abstract][Full Text] [Related]
17. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
18. NKG2D and its ligands.
Obeidy P; Sharland AF
Int J Biochem Cell Biol; 2009 Dec; 41(12):2364-7. PubMed ID: 19631280
[TBL] [Abstract][Full Text] [Related]
19. Viral inhibitors of NKG2D ligands for tumor surveillance.
Chávez-Blanco A; Chacón-Salinas R; Dominguez-Gomez G; Gonzalez-Fierro A; Perez-Cardenas E; Taja-Chayeb L; Trejo-Becerril C; Duenas-Gonzalez A
Expert Opin Ther Targets; 2016 Nov; 20(11):1375-1387. PubMed ID: 27322108
[TBL] [Abstract][Full Text] [Related]
20. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.
Schmiedel D; Mandelboim O
Front Immunol; 2018; 9():2040. PubMed ID: 30254634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
